The START Center for Cancer Care
Welcome,         Profile    Billing    Logout  
 67 Trials 
105 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tolcher, Anthony W
KEYNOTE-E34, NCT05784688: Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Recruiting
1b/2a
142
US
TU2218 + Pembrolizumab
TiumBio Co., Ltd., Merck Sharp & Dohme LLC
Solid Tumor
12/26
12/28
NCT04946864: A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Suspended
1/2
65
US, RoW
APG-2575, APG2575, Palbociclib
Ascentage Pharma Group Inc.
Breast Cancer, Solid Tumor, Adult
08/24
10/24
Keynote MK-3475-B66, NCT03611868: A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Recruiting
1/2
230
US, RoW
Phase 1b: APG-115+pembrolizumab, KEYTRUDA®
Ascentage Pharma Group Inc., Merck Sharp & Dohme LLC
Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST)
12/24
03/25
CBX-12-101, NCT04902872: Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Active, not recruiting
1/2
130
US
CBX-12
Cybrexa Therapeutics
Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer, Colorectal Cancer, Pancreas Cancer, Appendix Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Esophagus Cancer, Urothelial Carcinoma, Sarcoma
01/25
03/25
NCT04645069: ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

Completed
1/2
58
US, RoW
ADG126 Mono, ADG126-anti PD1, ADG126-ADG106
Adagene Inc
Advanced/Metastatic Solid Tumors
01/24
05/24
ELU-FRα-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Terminated
1/2
79
US
ELU001, FA-CDC
Elucida Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
06/24
06/24
NCT05417321: A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

Recruiting
1/2
80
US, RoW
HB0036, Anti-PD-L1 and anti-TIGIT bifunctional molecule
Shanghai Huaota Biopharmaceutical Co., Ltd.
Advanced Solid Tumor, NSCLC
08/25
08/25
NCT05159388: A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors

Active, not recruiting
1/2
45
Europe, US, RoW
PRS-344/S095012
Servier Bio-Innovation LLC, Institut de Recherches Internationales Servier
Solid Tumor
07/25
07/25
GLIMMER-01, NCT05259696: Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein

Active, not recruiting
1/2
273
US
E-602, Cemiplimab, Libtayo, REGN2810
Palleon Pharmaceuticals, Inc.
Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
06/25
06/25
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
PC14586, rezatapopt, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer
03/26
07/26
NCT03986606: A Study of PSB205 in Subjects With Advanced Solid Tumors

Recruiting
1
64
US
PSB205
Qilu Puget Sound Biotherapeutics (dba Sound Biologics), Pharmaceutical Research Associates
Neoplasm Malignant
02/21
07/21
NCT04686383: Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

Completed
1
17
US, RoW
CAL056 mesylate
Calgent Biotechnology Co., Ltd
Resistant or Refractory Solid Tumors
06/22
06/22
KEYNOTE-C97, NCT05277402: ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Completed
1
6
US
ADG116, Pembrolizumab (KEYTRUDA®)
Adagene Inc, Merck Sharp & Dohme LLC
Advanced/Metastatic Solid Tumors
08/22
12/22
NCT04430348: PTX-35 in Patients With Advanced Solid Tumors

Terminated
1
22
US
PTX-35
Pelican Therapeutics, Inc.
Advanced Solid Tumor
11/22
06/23
NCT03821233: A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Completed
1
112
Canada, US, RoW
ZW49
Zymeworks BC Inc.
HER2-expressing Cancers
09/24
10/24
ADG116-1003, NCT04501276: A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients

Active, not recruiting
1
72
US, RoW
ADG116, ADG106, anti PD1 drug
Adagene Inc
Advanced/Metastatic Solid Tumors
01/24
02/25
NCT04958434: Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Terminated
1
19
US
TST005
Suzhou Transcenta Therapeutics Co., Ltd.
Locally Advanced or Metastatic Cancers, Metastatic Human Papillomavirus-Related Malignant Neoplasm
09/23
09/23
NCT06270082: Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Recruiting
1
150
US
IK-595
Ikena Oncology
Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma, Ras (Kras or Nras) Gene Mutation, BRAF Gene Mutation, CRAF Gene Mutation, Non-Small Cell Lung Carcinoma, Thyroid Carcinoma, Gliomas, Malignant
07/27
07/27
NCT03819387: A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Completed
1
49
US
NBF-006
Nitto BioPharma, Inc.
Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
11/23
03/24
DDRiver Solid Tumours 301, NCT04170153: Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Active, not recruiting
1
161
Europe, Japan, US, RoW
M1774, Tuvusertib, Niraparib
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Metastatic or Locally Advanced Unresectable Solid Tumors
01/26
01/26
NCT05228015: Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

Terminated
1
67
Europe, US, RoW
IK-930, Osimertinib
Ikena Oncology
Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE), NF2 Deficient Mesothelioma, Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes, NF2 Deficiency, YAP1 or TAZ Gene Fusions
08/24
09/24
ATX-559-001, NCT06625515: First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers

Recruiting
1
100
US
ATX-559
Accent Therapeutics
Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer, Rectal Adenocarcinoma, Endometrial Cancer
10/26
02/27
NCT06797336: A Study of PT0253 in Participants with KRAS G12D Mutated Advanced Solid Tumors

Recruiting
1
115
US
PT0253
PAQ Therapeutics, Inc.
Solid Tumor
12/26
06/27
C-1100-01, NCT04121676: Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

Completed
1
91
US
AGEN2373, Anti-CD137, Botensilimab, AGEN1181, Anti-CTLA-4
Agenus Inc.
Advanced Cancer
02/24
11/24
NCT06098651: A Study of DCR-STAT3 in Adults With Solid Tumors

Recruiting
1
32
US
DCR-STAT3
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Solid Tumor, Adult, Refractory Tumor
07/25
07/25
ASN004, NCT04410224: Study of in Patients With Advanced Solid Tumors

Completed
1
19
US
ASN004
Kirilys Therapeutics Inc.
Solid Tumor
05/24
05/24
Patnaik, Amita
PRECISION 1, NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes

Active, not recruiting
2
120
US, RoW
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
12/24
12/25
EMBER, NCT04188548 / 2019-003581-41: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Active, not recruiting
1
500
Europe, Japan, US, RoW
LY3484356, Imlunestrant, Abemaciclib, LY2835219, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab
Eli Lilly and Company
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
06/20
12/27
INV-1120-101, NCT04443088: An Open-Label Study of INV-1120 As a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid Tumors

Active, not recruiting
1
78
US
INV-1120, Pembrolizumab, KEYTRUDA®
Shenzhen Ionova Life Sciences Co., Ltd., Merck Sharp & Dohme LLC
Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma, Solid Tumor, Unspecified, Adult, Tumor, Solid
03/26
12/26
NCT05661461: Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

Recruiting
1
28
US
nab-sirolimus, ABI-009, nab-rapamycin, albumin-bound rapamycin
Aadi Bioscience, Inc.
Tumor, Solid, Tumor, Advanced Solid Tumor
04/25
04/25
SGNCEA5C-001, NCT06131840: A Study of PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors

Recruiting
1
410
Europe, Canada, US
PF-08046050, SAR445953; SGN-CEACAM5C
Seagen Inc., Sanofi
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma
03/30
03/30
KEYNOTE-C16, NCT04374877: Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Recruiting
1
260
US, RoW
CHS-388, Casdozokitug, Pembrolizumab, Keytruda®, Toripalimab, Loqtorzi®
Coherus Biosciences, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
12/25
08/26
NCT06428500: QTX3046 in Patients with KRAS G12D Mutations

Recruiting
1
240
US
QTX3046, Cetuximab
Quanta Therapeutics
Advanced Solid Tumor
07/27
07/27
SGNB6A-001, NCT04389632: A Study of SGN-B6A in Advanced Solid Tumors

Recruiting
1
824
Europe, US, RoW
sigvotatug vedotin, SGN-B6A, pembrolizumab, Keytruda, cisplatin, carboplatin
Seagen Inc.
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
11/26
02/28
NCT06466187: A Study of PF-08052666/SGN-MesoC2 in Advanced Solid Tumors

Recruiting
1
365
US
PF-08052666, HBM9033; SGN-MesoC2
Seagen Inc.
Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial
11/28
11/28
NCT06586515: A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Recruiting
1
530
Europe, Canada, Japan, US
LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil
Eli Lilly and Company, Loxo Oncology, Inc.
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
03/29
03/29
NCT06607185: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Recruiting
1
750
Europe, Japan, US, RoW
LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Eli Lilly and Company
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
01/30
01/30
NCT06638307: A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Recruiting
1
124
Europe, US, RoW
MEN2312, Elacestrant
Stemline Therapeutics, Inc.
Advanced Breast Cancer
10/25
10/26
NCT05103046: First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors

Recruiting
1
68
US
UCT-03-008
1200 Pharma, LLC, Translational Research in Oncology
Advanced Solid Tumor
12/24
12/25
QTX3544-201, NCT06715124: QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations

Recruiting
1
237
US
QTX3544, Cetuximab
Quanta Therapeutics
Advanced Solid Tumors
01/27
01/29
SGNSTNV-001, NCT04665921: A Study of SGN-STNV in Advanced Solid Tumors

Terminated
1
111
Europe, Canada, US
SGN-STNV
Seagen Inc.
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
03/24
03/24
SGNB7H4V-001, NCT05194072: A Study of SGN-B7H4V in Advanced Solid Tumors

Active, not recruiting
1
572
Europe, Canada, US
SGN-B7H4V, Pembrolizumab, Keytruda
Seagen Inc.
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma
11/27
11/27
SGNPDL1V-001, NCT05208762: A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Recruiting
1
438
Europe, Canada, US
PF-08046054, SGN-PDL1V, pembrolizumab, Keytruda
Seagen Inc.
Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Ovarian Neoplasms, Melanoma, Triple Negative Breast Neoplasms, Gastric Cancer
07/25
12/27
SRF114-101, NCT05635643: Study of CHS-114 in Participants With Advanced Solid Tumors

Hourglass Jan 2024 - Jun 2024 : Results from SRF114-101 trial for advanced solid tumors
Recruiting
1
47
US
CHS-114, toripaliamab, Loqtorzi
Coherus Biosciences, Inc.
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
02/26
02/26
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
Zhai, Yifan
NCT04568265: A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B

Recruiting
2
122
RoW
APG-1387, Entecavir 0.5 mg, Baraclude
Ascentage Pharma Group Inc.
Hepatitis B, Chronic Hep B, HBV
10/22
10/25
NCT04496349: A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

Recruiting
2
78
US
APG-115, APG-2575
Ascentage Pharma Group Inc.
T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma
05/26
05/27
NCT05147467: Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Recruiting
2
75
RoW
APG2575
Ascentage Pharma Group Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
09/24
12/24
Keynote MK-3475-B66, NCT03611868: A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Recruiting
1/2
230
US, RoW
Phase 1b: APG-115+pembrolizumab, KEYTRUDA®
Ascentage Pharma Group Inc., Merck Sharp & Dohme LLC
Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST)
12/24
03/25
NCT04358393: A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

Recruiting
1/2
69
US
APG-115, 5-azacitidine, Vidaza, Azadine
Ascentage Pharma Group Inc.
AML, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, CMML, Myelodysplastic Syndromes, High-risk Myelodysplastic Syndrome, MDS
12/24
12/25
NCT04674514: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma

Recruiting
1/2
48
RoW
APG-2575, Rd, Lenalidomide +Dexamethasone
Ascentage Pharma Group Inc.
Multiple Myeloma
01/24
05/24
NCT04643405: APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

Recruiting
1/2
44
RoW
APG-1387 for Injection, Gemcitabine, Nab paclitaxel
Ascentage Pharma Group Inc.
Advanced Pancreatic Cancer
12/24
12/24
NCT04284488: Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Recruiting
1/2
104
RoW
APG-1387 for Injection, Toripalimab, JS001
Ascentage Pharma Group Inc.
Advanced Solid Tumor
04/24
04/24
APG2575AC101, NCT04501120: Study of APG2575 Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Recruiting
1/2
284
RoW
APG-2575, Reduced-dose HHT, standard-dose HHT, Azacitidine
Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.
Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy
08/25
08/26
APG2575MU101, NCT04942067: APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

Recruiting
1/2
108
US
APG-2575+ Pd, APG-2575+ Pomalidomide + Dexamethasone, APG-2575 + DRd, APG-2575+ Lenalidomide +Dexamethasone+Daratumumab
Ascentage Pharma Group Inc.
Multiple Myeloma, Amyloidosis
09/24
12/24
NCT04494503: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Recruiting
1/2
123
RoW
APG-2575, Rituximab, Ibrutinib
Ascentage Pharma Group Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
12/24
12/25
NCT05186012: APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Recruiting
1/2
51
RoW
APG-1252, Pelcitoclax, Chidamide
Ascentage Pharma Group Inc.
NHL, Adult
09/25
03/26
NCT03537482: APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

Recruiting
1
90
US, RoW
APG-2575
Ascentage Pharma Group Inc.
Hematologic Malignancies
09/24
02/25
NCT04215809 / 2020-002736-73: Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Recruiting
1
35
US, RoW
APG2575
Ascentage Pharma Group Inc.
CLL/SLL
03/25
06/26
HQP1351CU101, NCT04260022: Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Recruiting
1
62
US
Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab, Blincyto
Ascentage Pharma Group Inc.
Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia, B Cell Precursor Type Acute Leukemia
01/24
01/24
NCT05415098: Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Recruiting
1
90
US
APG-5918
Ascentage Pharma Group Inc.
Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma, Mesothelioma, Sarcoma, Non Hodgkin Lymphoma, B Cell Lymphoma, Epithelioid Sarcoma
09/24
09/25
Rasco, w
EIK1003-001, NCT06253130: A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Recruiting
1/2
70
US, RoW
IMP1734
Eikon Therapeutics, Impact Therapeutics, Inc.
Advanced Solid Tumor
02/26
12/26
NCT05267626: Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Recruiting
1/2
159
US, RoW
AU-007, Aldesleukin, Avelumab
Aulos Bioscience, Inc.
Advanced Solid Tumor, Metastatic Cancer
08/25
09/25
NCT05070247: A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
313
US
TAK-500, Pembrolizumab
Takeda
Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
08/26
08/26
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
49
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
11/25
11/25
FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
210
Europe, US, RoW
CPI-0209
Constellation Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
12/25
03/26
NCT06759649: A Clinical Trial to Assess COM503 in Participants with Advanced Solid Malignancies

Recruiting
1
200
US
COM503, Zimberelimab
Compugen Ltd, Gilead Sciences
Neoplasm, Cancer, Malignant Tumors
11/27
11/27
NCT05156866: First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

Recruiting
1
70
US, RoW
TORL-2-307-ADC
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
01/25
01/26
MT-6402-001, NCT04795713: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Terminated
1
64
US
MT-6402
Molecular Templates, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
10/24
10/24
CLN-619-001, NCT05117476: A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Recruiting
1
410
Europe, US, RoW
CLN-619, Pembrolizumab
Cullinan Therapeutics Inc.
Advanced Solid Tumor
03/26
06/26
NCT04446351: Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Recruiting
1
244
Canada, Japan, US, RoW
GSK6097608, Dostarlimab, Cobolimab, Belrestotug, GSK4428859A, EOS884448
GlaxoSmithKline, 23andMe, Inc., iTeos Therapeutics
Neoplasms
09/25
09/25
NCT05277051: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Recruiting
1
141
Europe, Canada, Japan, US, RoW
GSK4381562, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
GlaxoSmithKline
Neoplasms
09/28
09/28
FX-909-CLINPRO-1, NCT05929235: A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Recruiting
1
75
US
FX-909
Flare Therapeutics Inc.
Advanced Solid Tumors Cancer, Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
09/26
01/27
KISIMA-02, NCT05846516: A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC

Recruiting
1
85
Europe, US
VSV-GP154, ATP150, ATP152, Ezabenlimab
Amal Therapeutics, Boehringer Ingelheim
Pancreatic Ductal Adenocarcinoma
12/26
03/27
NCT04631445: Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer

Active, not recruiting
N/A
32
US
Ketogenic Diet
Translational Drug Development, Translational Genomics Research Institute
Metastatic Pancreatic Ductal Adenocarcinoma
03/25
04/25
Papadopoulos, Kyriakos
FOG-001-101, NCT05919264: FOG-001 in Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
480
US
FOG-001, mFOLFOX-6, Leucovorin, 5-fluorouracil, Oxaliplatin, Nivolumab, Opdivo, Trifluridine/tipiracil, Lonsurf, Bevacizumab, Avastin
Parabilis Medicines, Inc.
Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, WNT Pathway, β-catenin, Beta-catenin, Adenomatous Polyposis Coli, APC, HCC, Desmoid, Microsatellite Stable Colorectal Cancer, Metastatic Castration-resistant Prostate Cancer, FAP, Endometrial Carcinoma, Prostate Cancer, Microsatellite Instability-High Colorectal Cancer, CTNNB1, Adamantinomatous Craniopharyngioma
04/27
08/27
NCT04247126: A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

Completed
1
105
US
SY-5609, Fulvestrant, Gemcitabine, Nab-paclitaxel
Syros Pharmaceuticals
Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer, Pancreatic Cancer
01/23
03/23
KEYNOTE-C82, NCT04648202: FS120 Phase 1/1b Study in Patients With Advanced Malignancies

Active, not recruiting
1
82
Europe, US
FS120, Pembrolizumab (KEYTRUDA®)
invoX Pharma Limited, Merck Sharp & Dohme LLC
Advanced Cancer, Metastatic Cancer
03/26
03/26
STC15-22101, NCT05584111: Oral Administration of STC-15 in Subjects With Advanced Malignancies

Active, not recruiting
1
42
US
STC-15, METTL-3 Inhibitor
STORM Therapeutics LTD
Advanced Cancer, Advanced Solid Tumor, Cancer
12/24
03/25
MER-XMT-2056-1, NCT05514717: A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

Recruiting
1
162
US
XMT-2056
Mersana Therapeutics
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Non-Small Cell Lung Cancer, HER2-positive Colorectal Cancer, HER2-positive Tumors, HER2 Low Breast Cancer
04/27
04/27
KZR-261-101, NCT05047536: KZR-261 in Subjects With Advanced Solid Malignancies

Active, not recruiting
1
61
US
KZR-261, KZR-261 for Injection
Kezar Life Sciences, Inc.
Advanced/Metastatic Solid Tumor
12/25
12/26
NCT05841563: Clinical Trial of PM54 in Advanced Solid Tumors Patients.

Recruiting
1
125
Europe, US
PM54
PharmaMar
Advanced Solid Tumor
03/26
03/26
Jimenez, Isabel
TWT-101, NCT04521413: Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

Recruiting
1/2
170
Canada, US, RoW
CFI-402411, 2411, 402411, Pembrolizumab, Keytruda, pembro
Treadwell Therapeutics, Inc, TIO Discovery Engine
Advanced Solid Malignancies
11/24
12/24
NCT06244992: PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
68
US
PTT-936, Combination of PTT-936 and anti-PD-1/L1 therapy
Pyrotech Therapeutics, Inc.
Locally Advanced or Metastatic Solid Tumors
12/25
02/26
KEYNOTE-B47, NCT04130516: Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab

Recruiting
1/2
200
US
LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody, KEYTRUDA®, Pembrolizumab
Linnaeus Therapeutics, Inc., Merck Sharp & Dohme LLC
Solid Tumor, Adult
12/26
12/27
NCT03520075 / 2018-004568-72: Study of ASTX029 in Subjects With Advanced Solid Tumors

Active, not recruiting
1/2
190
Europe, US
ASTX029
Taiho Oncology, Inc.
Solid Tumor, Adult
08/24
12/25
PMD-026-1-001, NCT04115306: Phase 1/1b/2 Study of Oral PMD-026 in Patients with Metastatic Breast Cancer

Recruiting
1/2
61
US
PMD-026, fulvestrant, Faslodex
Phoenix Molecular Designs
Metastatic Breast Cancer
12/25
03/26
BBI-20201001, NCT04278144 / 2021-006812-10: A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Active, not recruiting
1/2
175
Europe, US, RoW
BDC-1001, Nivolumab, Opdivo
Bolt Biotherapeutics, Inc., Bristol-Myers Squibb
HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer, HER2-positive Endometrial Cancer
01/25
01/26
KB-0742-1001, NCT04718675: A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

Active, not recruiting
1/2
280
Europe, US
KB-0742
Kronos Bio
Relapsed Solid Tumors, Refractory Solid Tumors, Non-Hodgkin Lymphoma, HGSOC, Platinum Resistant High Grade Serous Ovarian Cancer
12/25
12/25
SNS-101-2-1, NCT05864144: A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Recruiting
1/2
169
US
SNS-101 (anti-VISTA), Cemiplimab
Sensei Biotherapeutics, Inc., Regeneron Pharmaceuticals
Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
06/27
06/27
SGNCEA5C-001, NCT06131840: A Study of PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors

Recruiting
1
410
Europe, Canada, US
PF-08046050, SAR445953; SGN-CEACAM5C
Seagen Inc., Sanofi
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma
03/30
03/30
STC15-22101, NCT05584111: Oral Administration of STC-15 in Subjects With Advanced Malignancies

Active, not recruiting
1
42
US
STC-15, METTL-3 Inhibitor
STORM Therapeutics LTD
Advanced Cancer, Advanced Solid Tumor, Cancer
12/24
03/25
QTX3034-001, NCT06227377: QTX3034 in Patients With KRAS G12D Mutation

Recruiting
1
250
US
QTX3034, Cetuximab
Quanta Therapeutics
Solid Tumors
04/27
04/27
NCT06428500: QTX3046 in Patients with KRAS G12D Mutations

Recruiting
1
240
US
QTX3046, Cetuximab
Quanta Therapeutics
Advanced Solid Tumor
07/27
07/27
SGNB6A-001, NCT04389632: A Study of SGN-B6A in Advanced Solid Tumors

Recruiting
1
824
Europe, US, RoW
sigvotatug vedotin, SGN-B6A, pembrolizumab, Keytruda, cisplatin, carboplatin
Seagen Inc.
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
11/26
02/28
NCT06466187: A Study of PF-08052666/SGN-MesoC2 in Advanced Solid Tumors

Recruiting
1
365
US
PF-08052666, HBM9033; SGN-MesoC2
Seagen Inc.
Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial
11/28
11/28
SGNSTNV-001, NCT04665921: A Study of SGN-STNV in Advanced Solid Tumors

Terminated
1
111
Europe, Canada, US
SGN-STNV
Seagen Inc.
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
03/24
03/24
MT-6402-001, NCT04795713: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Terminated
1
64
US
MT-6402
Molecular Templates, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
10/24
10/24
SGNB7H4V-001, NCT05194072: A Study of SGN-B7H4V in Advanced Solid Tumors

Active, not recruiting
1
572
Europe, Canada, US
SGN-B7H4V, Pembrolizumab, Keytruda
Seagen Inc.
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma
11/27
11/27
SGNPDL1V-001, NCT05208762: A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Recruiting
1
438
Europe, Canada, US
PF-08046054, SGN-PDL1V, pembrolizumab, Keytruda
Seagen Inc.
Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Ovarian Neoplasms, Melanoma, Triple Negative Breast Neoplasms, Gastric Cancer
07/25
12/27
 

Download Options